{"name":"North America Generics","slug":"dr-reddys","ticker":"RDY","exchange":"NYSE","domain":"drreddys.com","description":"Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and","hq":"Hyderabad, India","founded":2000,"employees":"27811","ceo":"Erez Israeli","sector":"Generics / Biosimilars","stockPrice":13.17,"stockChange":0.22,"stockChangePercent":1.7,"marketCap":"$11.0B","metrics":{"revenue":345831014400,"revenueGrowth":4.4,"grossMargin":55.2,"rdSpend":0,"netIncome":56587001856,"cash":82588999680,"dividendYield":0.7,"peRatio":18,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Lipitor patent cliff ($1.5B at risk)","drug":"Lipitor","type":"patent_expiry","sentiment":"negative"},{"date":"2029-06-01","label":"Plavix patent cliff ($1.2B at risk)","drug":"Plavix","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"RDY Reports Q4 2023 Earnings","summary":"North America Generics reported Q4 2023 earnings, with revenue of $1.2B and net income of $250M.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"RDY Partners with Biocon to Develop Biosimilars","summary":"North America Generics partnered with Biocon to develop and commercialize biosimilars in the US market.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves RDY's Generic Version of Eliquis","summary":"The FDA approved North America Generics' generic version of Eliquis, a blood thinner developed by Bristol-Myers Squibb and Pfizer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-08","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"6-K filed with SEC: FORM 6-K","headline":"6-K Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPbF9zSS1MTS1jWXl5MlFHUTBJOFA4WnpBa3pIRjBrM0p0NzJObVplNEI2bjZyYWVPWjBGTjhTNUszUml4UFNoZkJjNjRINFNuZEpvRzhZN3QyLW95VWtjdF9rcTZNaVN1OVFYQm5JOFpaYXBSamtZTk9rMzBZcHVFRWhSNC1vZi1WYVhjLTZaeWhVc2lpUmVsT1kyOVVfM1h2bnVuS183bm9JYU1RNmpoYjVyclRUdjJJb2tvZ1hrWFBSRUNIaEhtYjB3RnlwZGh3VTRhYTVMTk1HcWMyUHIxb1Z4Y3NlbTMxdmFNVU5ia0M?oc=5","date":"2026-03-05","type":"pipeline","source":"The Globe and Mail","summary":"Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's - The Globe and Mail","headline":"Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQWmFkWXdSalNCNEN5Qk5GeHJYZ0k1NXEzRFJuZjMwNG5tWHc0VHdpSWlNLWJnNDMzeU94bXhmWjVpRGJ1VzJGMDBCNFpRdFRhOXJYMXE0ckVNNUNJM3hyUjM1NmY3V291N19ZNUFZZzdiV3V0Uzc2ck90VUZWdTlGejdfS2VKcnJfZXBrTGh4bDdBeHFBOWk4Ymg4d3BNU010Q0xYNHc3TFNCM1N6am5zMHhlUE1IZVAxS1JuODZrZVE?oc=5","date":"2025-10-27","type":"earnings","source":"TradingView","summary":"Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues - TradingView","headline":"Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBYM2FuYzY2MjhoOTZzSjM1ZW5jUy1IUlV2dlBHUlpJOW1lSW16STM1WkkxaTFPczZvUy0zZUxkZVUxbGVBSDR4LVI1Z0xoOHA1aXAxblFR?oc=5","date":"2025-06-29","type":"pipeline","source":"Stock Titan","summary":"RDY SEC Filings - Dr Reddys Labs 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"RDY SEC Filings - Dr Reddys Labs 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNTTB3cjdja3VFRlJoZDdTYXFyaFRHTTVHam1MQ1FuNlZCS3h4ZjN6dlVtMU9xWVN6TmJhMFFjZm03clhwZENCRF9rdTlmS0N4SlZrR2FjT25HMU5IUllpb2xzZlBKTl9UWXlDZTdjSkdJUGZoMEdwMXpFQnJKTkV6cEhmbVNBR0hSUFdfY2RHaW9kemNySjVscGVVZHFLM0QwcnE1X01GREN2SmNiZk5Uc1kxX0lab3E3ZUdZalNwdV9OX1FkcVdQUFBBYkZHVVhXdTV6N0NDSHFmYXVfQmpSdTVaVFZodlNRQkZ1dFlFVklRLU52RUVTcmU5bHBhdw?oc=5","date":"2023-02-27","type":"deal","source":"Business Wire","summary":"Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio - Business Wire","headline":"Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxPNWlHenJpZ3N5ZzdNTVRPQ0NIZS1RUFVCQjVUM19YQ0lCa0xraVV4SjctWVpjbC1uSjg5MEVnSTNlalEta2h5OUdpc1VGbnVRRzNYUXM0bXotRTI0Wl9QcFZDYUZjY3VZVktSTFRSSzFlUTc4Vl81ODhydEhjdzlZWmxPS3U4aml1NFZNbTY0ek1uZFpseVctN0FfNVRlY0NfcjB2di1rbkZYMldqVXlGZC1lTzVoRFJwb01uaVFxRU9DcnFHTU93VXhVN0lLaFRBUUtBc0dTVUMwal9aaTh4NXFsOWZUM1NXSThWY1EyTldrektuM3FyMU16SlZLN1BFVUpCTU5TQWNjWjZ3TXA3TGZJTkcyb1NnRTZ2U2F0Ullidw?oc=5","date":"2022-05-24","type":"pipeline","source":"Business Wire","summary":"Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market - Business Wire","headline":"Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOOHVSQ3RIcGhfRTFSWlJXdFhqX1JtbEdRNTVJdW95cURCX2doNjRzZWt0MTN3RDF2ZGdlQVlINmp2X3VEU1A0bGRQQ3psaWN2QVFPSDdBWC1zV1BmbHBJSlh1VnBvWTBGVVJSOTNKVkY1YWhSN3owLTdrSTRPUlQxNzJoQkh4NnFGb043dk1VdW9XcGdLRUhXaUVsTUx4bVZCcVpHREdVbWRDNUVZZDhjSk9wNjA5Zw?oc=5","date":"2021-05-14","type":"pipeline","source":"Pharmacy Times","summary":"Dr. Reddy's Laboratories Announces Launch of Ertapenem for Injection in US Market - Pharmacy Times","headline":"Dr. Reddy's Laboratories Announces Launch of Ertapenem for Injection in US Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE16SnFwQUM0UVhUN195WlMtRHhXNlBEbVE0ZENUcmk0dEwySFpOeVRDMUlYamRTby1xQS1nWjZyNERMNEtjR2tZWXlxQlA?oc=5","date":"2020-09-29","type":"regulatory","source":"Stock Titan","summary":"Latest RDY News - Dr. Reddy’s Announces USFDA Acceptance to Re... - Stock Titan","headline":"Latest RDY News - Dr. Reddy’s Announces USFDA Acceptance to Re...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNV0ZMbTlVbEdxNm5YME5VeG9DOTlxdU82dEhVTGV6enZnMGdCRW1EeGU4N1lhRVcycW9pZ3N1WmFhNlR1NC1lam1oaV9HdVlfZjFxLU1rOFpzT0ZpMkQzZURQU1V2TkdSSjktV3Bsb3I5YnBOeEJjejJMV3E2NzFqYnlhZ2Y1Nng4eVktWUlJemlOUnpvZ0c1N0l2YmNJdGpqR0lYZHlJS0tCNjlDQ0lCaEhhUUFJOEkxcDdJT2N5QmMtckpOUlFvQ1gtNGstTWpqc29lNEpfeUhWUkRWRFlmdS1UVUUxMnZ4NEs5THY3U3RTems?oc=5","date":"2020-03-20","type":"patent","source":"BioSpace","summary":"Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Daraprim® in the U.S. Market - BioSpace","headline":"Dr. Reddy's Laboratories Announces the Launch of Pyrimethamine Tablets USP, 25 mg, First-Wave Generic Version of Darapri","sentiment":"neutral"}],"patents":[{"drugName":"Lipitor","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Plavix","drugSlug":"clopidogrel","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sandoz","Teva Pharmaceuticals","Mylan"],"therapeuticFocus":["Cardiovascular","Oncology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.17,"previousClose":12.95,"fiftyTwoWeekHigh":16.17,"fiftyTwoWeekLow":12.26,"fiftyTwoWeekRange":"12.26 - 16.17","fiftyDayAverage":14.02,"twoHundredDayAverage":14.15,"beta":0.3,"enterpriseValue":-527053984,"forwardPE":23.8,"priceToBook":2.75,"priceToSales":0.03,"enterpriseToRevenue":0,"enterpriseToEbitda":-0.01,"pegRatio":3.64,"ebitda":84786003968,"ebitdaMargin":24.5,"freeCashflow":13468874752,"operatingCashflow":63105998848,"totalDebt":67732000768,"debtToEquity":18,"currentRatio":1.88,"returnOnAssets":8,"returnOnEquity":16.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":5,"targetMeanPrice":14.22,"targetHighPrice":16.7,"targetLowPrice":11.32,"dividendRate":0.09,"payoutRatio":0.12,"fiveYearAvgDividendYield":0.72,"exDividendDate":1753401600,"insiderHeldPercent":0,"institutionHeldPercent":13.4,"sharesOutstanding":832594805,"floatShares":599191001,"sharesShort":13729535,"shortRatio":7.05,"shortPercentOfFloat":1.7,"epsTrailing":0.73,"epsForward":0.55,"revenuePerShare":69.37,"bookValue":4.78,"officers":[{"age":65,"name":"Mr. Gunupati Venkateswara Prasad B.E.","title":"Co-Chairman, MD & Member of Management Council"},{"age":58,"name":"Mr. Kallam Satish Reddy B.Tech., M.S.","title":"Chairman of the Board & Member of the Management Council"},{"age":57,"name":"Mr. Erez  Israeli M.B.A.","title":"CEO & Member of the Management Council"},{"age":55,"name":"Mr. Mannam  Venkatanarasimham","title":"CFO & Member of the Management Council"},{"age":52,"name":"Mr. Krishna K. Venkatesh B.Pharma M.S.","title":"Global Head of IPDO, Integrated Product Development & Member of the Management Council"},{"age":50,"name":"Mr. Deepak  Sapra M.B.A.","title":"Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council"},{"age":56,"name":"Mr. Motupalli Venkata Ramana M.B.A.","title":"CEO of Global Generics & Member of Management Council"},{"age":57,"name":"Mr. Sanjay  Sharma B.Tech.","title":"Executive VP, COO & Member of Management Council"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.drreddys.com","phone":"91 40 4900 2900"}}